Is FGFR2 fusion real target for bile tract cancer patients?

• Project/Area Number: 26860537
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Gastroenterology
• Research Institution: National Cancer Center Japan
• Principal Investigator: Shunsuke Kondo 国立研究開発法人国立がん研究センター, その他部局等, 研究員 (90546201)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000); Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000); Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 胆道がん / FGFR / 融合遺伝子 / 分子標的治療 / 阻害剤 / 分子標的治療薬

Outline of Final Research Achievements

In vitro assay using with cell lines of bile tract cancer, we conducted the stable of overexpression with FGFR2 fusion (FGFR2-AHCYL1& FGFR2-BICC1). We validated dephosphorylation of the stable cell lines. On the other hands, several biological changes were not observed between overexpression model and endogenous cell lines. Therefore, we have challenged established cell lines from the surgical specimens. In parallel, we have detected FGFR gene mutations and FGFR fusion genes using next generation sequencer. The clinical project, TOP-GEAR project, has been on going that screening of genomic profiles and matching target therapies.

Research Products

• [Journal Article] Trends in the development of MET inhibitors for hepatocellular carcinoma. (2016)
  • Author(s): Okuma HS, Kondo S.
  • Journal Title: Future Oncology Volume: 12 Issue: 10 Pages: 1275-1286
  • DOI: 10.2217/fon.16.3
  • Peer Reviewed / Open Access
• [Journal Article] Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. (2016)
  • Author(s): Shiba S, Morizane C, Hiraoka N, Sasaki M, Koga F, Sakamoto Y, Kondo S, Ueno H, Ikeda M, Yamada T, Shimada K, Kosuge T, Okusaka T.
  • Journal Title: Pancreatology Volume: 16 Issue: 1 Pages: 99-105
  • DOI: 10.1016/j.pan.2015.11.001
  • Peer Reviewed / Open Access
• [Journal Article] Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. (2016)
  • Author(s): Shoji H, Morizane C, Sakamoto Y, Kondo S, Ueno H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M, Okusaka T.
  • Journal Title: Japanese journal of clinical oncology Volume: 46 Pages: 132-137
  • DOI: 10.1093/jjco/hyv179
  • Peer Reviewed / Open Access
• [Journal Article] C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. (2016)
  • Author(s): Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Okuyama H, Ueno H, Morizane C, Kondo S, Sakamoto Y, Okusaka T, Ochiai A.
  • Journal Title: Pancreas Volume: 45 Issue: 1 Pages: 110-116
  • DOI: 10.1097/mpa.0000000000000465
  • Peer Reviewed / Open Access